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Biologic Features
Mucopolysaccharidosis (MPS) type VII (Sly syndrome)
was first described in a mixed-breed dog in 1984.1 Since
then, an additional 19 affected dogs have been studied in
the animal colony established at the University of Penn-
sylvania, School of Veterinary Medicine. All of the affected
dogs were descendants of a single carrier female and
were, therefore, homozygous for a single mutation in the
,B-glucuronidase gene. Typical features of the syndrome
that were evident in affected dogs by 4 weeks of age
included a shortened broad face, low-set ears, and a
laterally broad chest. Diffuse corneal clouding was evi-
dent by 8 weeks of age. By 9 weeks of age, affected
animals were approximately 50% smaller than littermates
and had a disproportionately large head. Polymorphonu-
clear leukocytes and lymphocytes in peripheral blood
smears contained coarse cytoplasmic granules (Alder-
Reilly bodies) that stained metachromatically with tolu-
idine blue. Affected animals also had a positive Berry
spot test2 for excessive urinary glycosaminoglycans
(GAGs), which were shown to be chondroitin 4- and 6-
sulfates and dermatan sulfate by cellulose acetate
electrophoresis.1 Signs of appendicular skeletal disease
were first evident between 2 and 5 months of age, when
affected animals could no longer stand, but were able to
move in sternal recumbency and eat and drink indepen-
dently. Synovial joint capsules were swollen and fluctu-
ant, with most joints extremely lax, easily subluxated, and
crepitant. Radiographic features of the disease included
severe, progressive, epiphyseal dysplasia and bilateral
hip subluxation to complete luxation. Cardiac abnormal-
ities were variable. Several affected animals had no clin-
ical signs of heart disease by 2 years of age, whereas
others had clinical signs of mitral insufficiency or patent
ductus arteriosus in the first week of life.
Significant pathologic changes were present in many
systems. Hepatomegaly, without splenomegaly, was
present. The trachea in all animals was misshapen with
variable degrees of narrowing resulting from overlapping
tracheal rings. Atrioventricular heart valve leaflets and
chordae tendinae were thickened, with the mitral valve
being the most affected. The closure of the ductus arte-
riosis was incomplete, resulting in either a patent ductus
arteriosus or a ductus diverticulum. The arch of the aorta
was thickened to some degree in all animals. In dogs
over 4 months of age, the synovial membranes were hy-
perplastic, and the articular cartilage and underlying
bone of most synovial joints was eroded. Histologically,
cytoplasmic vacuoles were present in central nervous
system neurons, hepatocytes, Kupffer cells, keratocytes,
retinal pigment epithelium, atrioventricular heart valve fi-
broblasts, aortic smooth muscle cells, leukocytes, chon-
drocytes, and synovial cells. By electron microscopy, the
cytoplasmic inclusions were membrane bound (Figures
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Figure 1. An electron photomicrograph of a polymorphonuclear
leukocyte with membrane-bound cytoplasmic inclusions (arrows)
fr-om an 11-day-old dog with MPS VII (N, a lobe of the nucleus; bar
1t) (lead citrate and uranyl acetate, x7700).
1 and 2) and were empty or contained granular or lamel-
lar material.
Activity of P-glucuronidase in peripheral blood leuko-
cytes and 10 other tissues ranged from 0.2% to 1.7% that
of normal canine values.3 Canine MPS VIl sera had about
6.4% of normal 3-glucuronidase activity and was used to
diagnose affected animals less than 3 weeks of age. Ob-
ligate heterozygotes for the disease had enzyme activi-
ties approximately 50% of normal.
Pedigree information (Figure 3) and enzyme activity of
sera from family members were consistent with autoso-
mal recessive inheritance. Male dogs of reproductive
age were fertile by artificial insemination. Two female
dogs were not observed to have estrus cycles by 24
months of age.
Figure 2. An electron photomicrograph of a hepatocyte from a
4-month-old dog with MPS VII. Note the large membrane-bound
cytoplasmic inclusions containingfine granular material (N, nu-
cleus; bar = 2 ) (lead citrate and uranyl acetate, x6000).
EI UNAFFECTED MALE MPS VII MALE
Q UNAFFECTED FEMALE MPS VII FEMALE
0 UNAFFECTED SEX UNKNOWN MPS VII SEX UNKNOWN
Figure 3. The pedigree of the family of dogs with MPS VII. 7he
propositus (arrow) was reported to have been the offspring of a
father-daughter mating, but that information could not be con-
firmed All other affected dogs were descendants of a single bet-
erozygousfemale and were therefore homozygousfor the identical




The clinical phenotype of MPS VII in man is variable.4
Patients range from those with severe mental retardation,
skeletal abnormalities, corneal clouding, and hepato-
splenomegaly to those with normal intelligence and stat-
ure, and little or no corneal clouding or skeletal abnor-
mality. All human patients have had leukocyte inclusions
and excreted excessive amounts of GAGs in their urine.
The clinical phenotype in the dog most closely resembles
the more severely affected human patients. Pathologic
lesions of MPS VIl in the dog and man are similar. In both
species there is storage of incompletely degraded GAGs
within membrane-bound cytoplasmic inclusions. The dis-
tribution of lesions in the dog also closely parallel those of
the human mucopolysaccharidoses in general, and MPS
VII in particular, affecting the skeletal, cardiac, ocular,
and central nervous systems. This naturally occurring an-
imal homolog is proving useful in studies of the patho-
genesis and approaches to therapy for lysosomal stor-
age diseases.5'6
Availability of the Model
The colony of dogs is available for collaborative research.
When the number of dogs with MPS VII exceeds the re-
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search needs of the authors, animals will be made avail-
able to others with an interest in using this animal model.
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